Dopamine D2 receptor — Drug Target
All drugs that target Dopamine D2 receptor — marketed and clinical-stage. Includes 14 drug classes acting on this target.
Drug classes
Dopamine agonist · First-generation antipsychotic (typical antipsychotic) · Dopamine antagonist / Prokinetic agent · Dopamine D2 receptor agonist · Dopamine antagonist / Antiemetic / Prokinetic agent · atypical antipsychotic · Butyrophenone antipsychotic · Atypical antipsychotic, long-acting injectable · Typical antipsychotic · Dopamine D2 receptor antagonist · Dopamine D2 receptor antagonist (antipsychotic) · Antipsychotic combination (long-acting injectable)
Marketed (6)
- Cabergoline (Dopamine Agonist) · University Hospital, Basel, Switzerland · Dopamine agonist · Endocrinology
Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland. - Haloperidol Injection · Hennepin Healthcare Research Institute · First-generation antipsychotic (typical antipsychotic) · Psychiatry
Haloperidol blocks dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission to treat psychotic symptoms and agitation. - Placebo domperidone · Seoul National University Hospital · Dopamine antagonist / Prokinetic agent · Gastroenterology
Domperidone is a dopamine antagonist that blocks dopamine receptors in the chemoreceptor trigger zone to reduce nausea and vomiting while promoting gastric motility. - combination with dopamine agonist cabergoline · Ludwig-Maximilians - University of Munich · Dopamine agonist · Endocrinology
Cabergoline is a dopamine agonist that stimulates dopamine D2 receptors to inhibit prolactin secretion from the anterior pituitary gland. - Cabergoline Pill · Fertility Center of Las Vegas · Dopamine D2 receptor agonist · Endocrinology / Reproductive Medicine
Cabergoline is a dopamine D2 receptor agonist that suppresses prolactin secretion from the pituitary gland. - Metoclopramide hydrochloride monohydrate · CM Chungmu Hospital · Dopamine antagonist / Antiemetic / Prokinetic agent · Gastroenterology
Metoclopramide blocks dopamine receptors in the chemoreceptor trigger zone and enhances acetylcholine effects on gastric muscle to increase gastric contractions and accelerate gastric emptying.
Phase 3 pipeline (11)
- Paliperidone ER OROS · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · atypical antipsychotic · Psychiatry
Paliperidone ER OROS is an atypical antipsychotic that works by blocking dopamine receptors in the brain. - Droperidol Injectable Product · Mercy Health Ohio · Butyrophenone antipsychotic · Psychiatry / Acute Care
Droperidol is a butyrophenone antipsychotic that blocks dopamine receptors in the central nervous system, reducing agitation and providing antiemetic effects. - RBP-7000 · Indivior Inc. · Atypical antipsychotic, long-acting injectable · Psychiatry
RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period. - Cabergoline tablets · Changchun GeneScience Pharmaceutical Co., Ltd. · Dopamine D2 receptor agonist · Endocrinology
Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland. - Intramuscular Haloperidol · Shanghai Mental Health Center · Typical antipsychotic · Psychiatry
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms and agitation. - Supemtek® · Assistance Publique - Hôpitaux de Paris · Dopamine D2 receptor antagonist · Psychiatry
Supemtek is a small molecule drug that targets the dopamine D2 receptor. - Bromocriptine mesylate tablets · Changchun GeneScience Pharmaceutical Co., Ltd. · Dopamine D2 receptor agonist · Endocrinology
Bromocriptine mesylate is a dopamine D2 receptor agonist that inhibits prolactin secretion and modulates hypothalamic-pituitary function. - Bromocriptine-QR · University of North Carolina, Chapel Hill · Dopamine D2 receptor agonist · Endocrinology / Cardiovascular
Bromocriptine-QR is a quick-release formulation of bromocriptine, a dopamine D2 receptor agonist that reduces prolactin secretion and modulates circadian rhythm regulation. - LY03005 extended-release tablet · Luye Pharma Group Ltd. · Dopamine D2 receptor antagonist (antipsychotic) · Psychiatry/Neurology
LY03005 is a dopamine D2 receptor antagonist that blocks dopamine signaling in the central nervous system. - ALKS 8700 · Biogen · Antipsychotic combination (long-acting injectable) · Psychiatry/Neurology
ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation. - Phase 1: Perphenazine · Shanghai Mental Health Center · Typical antipsychotic · Psychiatry
Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms.
Phase 2 pipeline (1)
- Current Domperidone · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Dopamine antagonist · Gastrointestinal
Current Domperidone acts as a dopamine D2 receptor antagonist.
Phase 1 pipeline (2)
- Antipsychotic therapy · FORUM Pharmaceuticals Inc · Atypical antipsychotic · Neurology
Antagonizes dopamine D2 receptors - 14C-paliperidone · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Atypical antipsychotic · Neurology
Dopamine D2 receptor antagonist